StockData

Septerna vs Wave Life Sciences

SEPN and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SEPN and WVE compare

Septerna is the larger company, worth 3.3 times as much as Wave Life Sciences ($1.9B against $560M).

Septerna keeps more of each dollar of sales as profit, with a net margin of −61.3% compared with −297% at Wave Life Sciences.

Wave Life Sciences scores higher on the StockData Score (10 against 8 for Septerna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSEPNWVE
Size and price
Market cap$1.9B$560M
Share price$40.02$2.84
Change, 1 year72.0%−59.9%
Change, 5 years–−28.8%
Beta (5Y)0.701.86
Employees130317
StockData Score
Total score810 (better)
Valuation score03 (better)
Growth score11
Performance score11
Health score6 (better)5
Dividend score00
Valuation
P/S19.4×7.9× (better)
P/B4.4×1.4× (better)
FCF yield−4.2% (better)−37.2%
Fair value$15.08$5.23
Margin of safety−165%45.7% (better)
Growth
Revenue growth (TTM)337%–
Revenue growth, 5Y average–16.3%
Profitability
Operating margin−76.2% (better)−321%
Net margin−61.3% (better)−297%
FCF margin−80.6% (better)−294%
Return on equity−14.4% (better)−80.0%
Financial health
Debt / equity0.000.00
Current ratio4.848.38 (better)
Altman Z-score5.91 (better)−1.30
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%92.6%
Held by insiders27.9%23.1%
Insider net buying, 12 months−$80.9M$66.5M (better)
Superinvestors holding–1
Short interest, % of float10.0%13.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.